Mesoblast (MESO) Operating Leases (2019 - 2026)
Mesoblast (MESO) posted Operating Leases of $5.9 million for Q4 2025, up 64.44% sequentially from $3.6 million in Q2 2025, and up 24.04% YoY from $4.8 million in Q4 2024.
Analysis
Mesoblast (MESO) Operating Leases (2019 - 2026) Analysis & Trends
Mesoblast has reported Operating Leases for 7 years, with the latest figure at $5.9 million in Q4 2025.
- Quarterly Operating Leases rose 24.04% year-over-year to $5.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (up 24.04% YoY) and the FY2025 annual result came in at $3.6 million, down 21.73% from the prior year.
- Operating Leases rose to $5.9 million in Q4 2025 per MESO's latest filing, from $3.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $10.3 million in Q2 2022 and troughed at $3.4 million in Q4 2023.
- A 5-year average of $6.3 million and a median of $6.3 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases sank 42.29% in 2023, then soared 40.28% in 2024.
- Over 5 years, Operating Leases stood at $7.9 million in 2021, then slumped by 37.04% to $5.0 million in 2022, then plunged by 32.28% to $3.4 million in 2023, then surged by 40.28% to $4.8 million in 2024, then grew by 24.04% to $5.9 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $5.9 million, $3.6 million, and $4.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.03 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Dec 31, 2024 | 2.38 Mn |
| Jun 30, 2024 | 2.63 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Jun 30, 2023 | 4.06 Mn |
| Mar 31, 2023 | 3.61 Mn |
| Dec 31, 2022 | 3.86 Mn |
| Sep 30, 2022 | 3.61 Mn |
| Jun 30, 2022 | 3.19 Mn |
| Mar 31, 2022 | 2.43 Mn |
| Dec 31, 2021 | 3.49 Mn |
| Sep 30, 2021 | 3.14 Mn |
| Jun 30, 2021 | 2.77 Mn |
| Mar 31, 2021 | 2.84 Mn |
| Dec 31, 2020 | 2.55 Mn |
| Sep 30, 2020 | 2.98 Mn |
| Jun 30, 2020 | 3.52 Mn |
| Mar 31, 2020 | 3.06 Mn |